Lithium orotate 

Lithium orotate is an orally active lithium supplement with reduced binding that can bypass amyloid sequestration in AD mice models. Lithium orotate can prevent Aβ plaque deposition and phospho-tau accumulation and reverse AD pathology, neuroinflammatory changes and memory loss in AD mice models and ageing wild-type mice. Lithium orotate can be used for the research of alcoholism and Alzheimer’s disease^[1][2].

Lithium orotate (0-500 μM; 16 h) has low binding ability to synthetic human Aβ_1-42 fibrils and oligomers^[2].
Lithium orotate (20-500 μM; 6 h pre-treatment) promotes microglial uptake and degradation of Aβ₄₂ in BV2 microglial cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lithium orotate (4.3-430 µM.;p.o.; in drinking water) prevents and reverses AD pathology and cognitive decline in AD mouse models and ageing wild-type mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

162.03

C₅H₃LiN₂O₄

5266-20-6

Solid

O=C1C=C(C(O[Li])=O)NC(N1)=O

Room temperature in continental US; may vary elsewhere.

• [1]. Sartori HE, et al. Lithium orotate in the treatment of alcoholism and related conditions. Alcohol. 1986;3(2):97-100.  [Content Brief]

  [2]. Aron L, et al. Lithium deficiency and the onset of Alzheimer's disease. Nature. 2025;645(8081):712-721.  [Content Brief]